Aravind Pothineni, MD
Pulmonary Disease · Cape Giradeau, MONPI 1124215124
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (49.7%), education and travel and lodging — rather than concentrated in one kind of arrangement. 35 manufacturers reported payments, led by Intuitive Surgical at 46.8% of the total. Reporting peaked in 2023 at $9,679 and has fallen 86.6% since, to $1,299 in 2025.
Across 385 payments — averaging $45.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$8K
- AstraZeneca$2K
- GSK$2K
- Pulmonx Corporation$898
- Boehringer Ingelheim$696
- Regeneron Healthcare Solutions, Inc.$624
- plus $3K from 29 others
What the payments were for
- Travel & lodging$2,55815%
- Food & beverage$8,73450%
- Education$6,27136%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 19 | $8,211 |
| AstraZeneca(2 entities) | 65 | $2,092 |
| GSK | 109 | $1,654 |
| Pulmonx Corporation | 4 | $898 |
| Boehringer Ingelheim | 18 | $696 |
| Regeneron Healthcare Solutions, Inc. | 23 | $624 |
| Jazz Pharmaceuticals Inc. | 19 | $585 |
| Mylan Specialty L.p. | 19 | $403 |
| Actelion Pharmaceuticals US, Inc. | 10 | $350 |
| United Therapeutics Corporation | 11 | $312 |
| Grifols USA, LLC | 15 | $292 |
| Insmed, Inc. | 15 | $258 |
| Sanofi | 9 | $188 |
| Harmony Biosciences LLC | 5 | $181 |
| Livanova USA, Inc. | 2 | $108 |
| Amgen | 6 | $97 |
| Merck | 6 | $93 |
| Johnson & Johnson(2 entities) | 4 | $81 |
| Novartis | 3 | $48 |
| Sunovion Pharmaceuticals Inc. | 2 | $46 |
| Eisai Inc. | 3 | $42 |
| Mallinckrodt Hospital Products Inc. | 2 | $40 |
| Cvrx, Inc. | 1 | $34 |
| Elutia, Inc. | 2 | $32 |
| Apria Healthcare LLC | 2 | $25 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $21 |
| Cardiva Medical, Inc. | 1 | $20 |
| Inspire Medical Systems, Inc. | 1 | $19 |
| Verona Pharma, Inc. | 1 | $18 |
| Viatris Specialty LLC | 1 | $17 |
| Pfizer | 1 | $17 |
| Teva Pharmaceuticals USA, Inc. | 1 | $15 |
| Axsome Therapeutics, Inc. | 1 | $15 |
| Olympus America Inc. | 1 | $15 |
| Electromed, Inc. | 2 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$4,701
- ION$3,000
- Pulmonx Endobronchial Valve EBV$827
- FASENRA$729
- BREZTRI$465
- TEZSPIRE$370
- AIRSUPRA$363
- OFEV$245
- TRELEGY ELLIPTA$224
- UPTRAVI$125
- OPSUMIT$125
- Yupelri$116
- XYWAV$114
- Wakix$111
How this compares
$17,562 in reported general payments places this provider in the 85th percentile of 295 pulmonary disease providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 47 | $601,802 |
| Dupixent PenDupilumab | 98 | $433,472 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 435 | $326,825 |
| NucalaMepolizumab | 43 | $272,360 |
| Fasenra PenBenralizumab | 31 | $191,652 |
| Prolastin CAlpha-1-Proteinase Inhibitor | 13 | $176,374 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 167 | $122,836 |
| Dupixent SyringeDupilumab | 25 | $101,064 |
| Ambrisentan | 20 | $75,037 |
| XolairOmalizumab | 26 | $49,868 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 69 | $39,413 |
| Spiriva RespimatTiotropium Bromide | 49 | $39,315 |
| SymbicortBudesonide/Formoterol Fumarate | 105 | $27,661 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 41 | $27,277 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 42 | $25,708 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat, Combivent Respimat | $696 | $707,807206 claims |
| GSKTrelegy Ellipta, Nucala, Anoro Ellipta, Breo Ellipta, Arexvy | $1,654 | $644,048565 claims |
| Grifols USA, LLCProlastin C | $292 | $176,37413 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $2,092 | $150,497272 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $15 | $6,57723 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 295 pulmonary disease providers in Missouri.
Other pulmonary disease in Cape Giradeau
- Humam FarahHannibal$840K
- Derek ByersSaint Louis$835K
- Alexander ChenSaint Louis$679K
- Joseph OjileSaint Louis$538K
- Munaf SiyamwalaIndependence$413K
- Edward CharbekSaint Louis$372K
- Adeel KhanWashington$316K
- Marin KollefSaint Louis$264K
- Praveen ChennaSaint Louis$255K
- Bobby ShahChesterfield$241K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.